Related Experiment Videos
Pathophysiology of endothelin in the cardiovascular system
1Department of Internal Medicine, University of Tsukuba, Ibaraki, Japan. t-mlyauc@md.tsukuba.ac.jp
Insights
Endothelin-1 plays a key role in cardiovascular diseases. Blocking endothelin receptors or inhibiting its production offers promising therapeutic strategies for heart failure and other conditions.
Area of Science:
- Pharmacology
- Biochemistry
- Cardiovascular Medicine
Background:
- Endothelin is a potent vasoconstrictor with significant roles in cardiovascular physiology and pathology.
- Endogenous endothelin-1 (ET-1) is implicated in various cardiovascular diseases, including heart failure, hypertension, and pulmonary hypertension.
Purpose of the Study:
- To review the pharmacological and biochemical properties of endothelin.
- To elucidate the pathophysiological roles of endothelin in cardiovascular diseases.
- To explore the therapeutic potential of endothelin pathway interference.
Main Methods:
- Review of existing literature on endothelin pharmacology, biochemistry, and pathophysiology.
- Analysis of studies investigating endothelin receptor antagonists in cardiovascular disease models.
- Examination of clinical trial data for endothelin-targeted therapies.
Main Results:
- Increased endothelin-1 expression and receptor activity are observed in conditions like chronic heart failure.
- Endothelin receptor antagonists have demonstrated improvements in survival and cardiac function in heart failure.
- These antagonists also show efficacy in treating other cardiovascular diseases such as hypertension and pulmonary hypertension.
Conclusions:
- The endothelin pathway is a critical target for cardiovascular disease intervention.
- Endothelin receptor blockade represents a viable therapeutic strategy for multiple cardiovascular conditions.
- Inhibition of the endothelin pathway offers novel drug development opportunities for cardiovascular diseases.
Abstract:
In this article, we review the basic pharmacological and biochemical features of endothelin and the pathophysiological roles of endothelin in cardiovascular diseases. Development of receptor antagonists has accelerated the pace of investigations into the pathophysiological roles of endogenous endothelin-1 in various diseases, e.g. chronic heart failure, renal diseases, hypertension, cerebral vasospasm, and pulmonary hypertension. In chronic heart failure, the expression of endothelin-1 and its receptors in cardiomyocytes is increased, and treatment with an endothelin receptor antagonist improves survival and cardiac function. Endothelin receptor antagonists also improve other cardiovascular diseases. These results suggest that the interference with endothelin pathway either by receptor blockade or by inhibition of endothelin converting enzyme may provide novel therapeutic drugs strategies for multiple disease states.